Introduction: In 2015, the UK health secretary made public an intention to include the value of medicines costing over £20 on dispensing labels as an attempt to reduce wastage attributable to patient behavior. However, there is a lack of evidence investigating the potential effect or feasibility of this proposal, and concerns have been raised that it may introduce new problems in vulnerable groups. This pilot study aimed to gather views of the Welsh general public on this subject.
Methods: Six focus groups from within key population groups were conducted. A snowball sampling strategy was employed with participants recruited via a neutral gatekeeper. Focus groups session were audio recorded and transcribed verbatim and iterative thematic analysis was used to identify emergent themes.
Results: Six focus groups were conducted. Three key themes were identified: "influence of cost" - whereby participants expressed concern about cost linking to their perceived value, guilt for needing prescribed medication and irrelevance of cost if the medication was considered necessary; "knowledge is power" - whereby participants expressed a desire to know more about their medicines and engage with health care professionals about them, and felt information on dispensing labels alone would be insufficient to support this and "blame the system" - whereby participants felt responsibility for wastage should be shared by both system and patient and identified existing wasteful practices such as inappropriate prescribing, ordering and disposal of returned medicines.
Conclusion: Findings were largely consistent with criticisms publicized by professional bodies that introducing cost may serve to make patients feel guilty or unworthy rather than encourage them to use their medicines appropriately. Similarly, providing cost information on labels alone was considered insufficient and therefore additional counseling or education would be necessary to prevent misunderstanding. The acknowledgment of system factors contributing to wastage highlights an important role for pharmacists to become involved in using medicines more cost-effectively. However, cost was considered irrelevant if the medicine was deemed necessary by the patient, and therefore more mindful prescribing of superfluous items should be promoted.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774318 | PMC |
http://dx.doi.org/10.2147/IPRP.S145567 | DOI Listing |
Subst Abuse Treat Prev Policy
January 2025
Griffith Centre for Mental Health, Griffith University, Brisbane, QLD, Australia.
Background: Legitimate androgen use, such as testosterone replacement therapy, requires a legal prescription. Off-label use for reasons like wellness and aesthetics continues to grow. Recent regulatory changes in Australia aim to curb non-prescribed androgen use, potentially intensifying stigma, however seeking prescriptions through legal channels persists.
View Article and Find Full Text PDFBMC Prim Care
January 2025
Département de psychiatrie, Centre de recherche de l'Institut universitaire en santé mentale de Montréal, Université de Montréal, Montreal, QC, Canada.
Objectives: This study identified profiles of outpatient physician follow-up care and other practice features, mostly after detection of incident mental disorders (MD), and associated these profiles with patient characteristics and subsequent adverse outcomes.
Methods: A cohort of 170,957 patients age 12 + with a new or recurrent MD detected in 2019-20 was investigated based on data from the Quebec Integrated Chronic Disease Surveillance System. Latent class analysis was performed to identify follow-up care profiles, mostly within one year of MD detection.
J Family Med Prim Care
November 2024
Department of Community Medicine, Indira Gandhi Medical College and Research Institute, Puducherry, India.
Background: Prescription auditing is a crucial tool for evaluating a range of concerns, including injectable usage, polypharmacy, the use of generic names, and the quality of treatment given to patients in primary care facilities. The objective of the study was to assess, using WHO core drug use indicators, the drug use patterns of general outpatients (OPD) at a rural healthcare facility.
Materials And Methods: A cross-sectional study was conducted in a rural peripheral health centre in Puducherry for a period of one year from September 2019 to August 2020.
Ment Health Clin
December 2024
(Corresponding author) Clinical Pharmacist Specialist, Vanderbilt Specialty Pharmacy Services, Nashville, Tennessee,
Vesicular monoamine transporter 2 inhibitors (VMAT2i) are currently Food and Drug Administration-approved for the treatment of Huntington disease chorea and tardive dyskinesia. Additionally, they are often used for other hyperkinetic movement disorders in clinical practice. Due to a lack of head-to-head clinical trials, management of VMAT2i in the clinical setting may be unclear and rely on the clinical experience of the practitioner.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!